GENTIAN VIOLET: WHAT WE KNOW AND WHAT IS AHEAD OF US

被引:3
作者
Dragan, Jedrzej [1 ]
Michalak, Sylwia Sulimiera [1 ]
机构
[1] Univ Zielona, Fac Med & Hlth Sci, Gora, Poland
来源
ACTA POLONIAE PHARMACEUTICA | 2019年 / 76卷 / 03期
关键词
p53; crystal violet; gentian violet; fungal infection; bacterial infection; STAPHYLOCOCCUS-AUREUS; OROPHARYNGEAL; CANDIDIASIS; METABOLISM; INFECTION; NYSTATIN; THERAPY;
D O I
10.32383/appdr/102482
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
At present, the only active substance of Gentian Violet (GV) is methylrosaniline - a triphenylmethane dye of which amino group contains 2 methyl groups. GV can be used to treat uncomplicated bacterial and/or yeast infections, support antibiotic therapy of more severe infections, but also to protect medical equipment against colonization by microorganisms. In the light of recent studies, there are many new possibilities for GV application. It has been shown to be effective in the treatment of viral infections, some chronic skin diseases and oncology. GV can induce apoptosis of tumor cells among others by elevating caspase 8, inhibiting NADPH oxidases, decreasing mitochondrial thioredoxin 2 or inhibiting STAT3/SOX2 axis. Preclinical and in vitro studies have also demonstrated GV efficacy in the treatment of breast cancer, melanoma tumors and cutaneous T-cell lymphoma. There is no unambiguous evidence indicating the toxicity of GV, whereas its safety has been proven by its long history of use, its inclusion in numerous guidelines and its legal trade and distribution with no specific approval requested in many countries around the world. The article gathers the available knowledge about GV and its potential use in the future.
引用
收藏
页码:389 / 396
页数:8
相关论文
共 50 条
  • [1] Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know
    van Duin, David
    VIRULENCE, 2017, 8 (04) : 379 - 382
  • [2] Illicit drugs in Central Asia: What we know, what we don't know, and what we need to know
    Latypov, Alisher
    Grund, Jean-Paul
    El-Bassel, Nabila
    Platt, Lucy
    Stoever, Heino
    Strathdee, Steffanie
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2014, 25 (06) : 1155 - 1162
  • [3] Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don't We Know?
    Baeten, Jared M.
    Grant, Robert
    CURRENT HIV/AIDS REPORTS, 2013, 10 (02) : 142 - 151
  • [4] Newborn screening conditions: What we know, what we do not know, and how we will know it
    Levy, Harvey L.
    GENETICS IN MEDICINE, 2010, 12 (12) : S213 - S214
  • [5] Fecal Microbiota Transplantation: What We Know and What We Need to Know
    Surawicz, Christina M.
    ANNALS OF INTERNAL MEDICINE, 2015, 162 (09) : 662 - 663
  • [6] Transmission of Ebola Viruses: What We Know and What We Do Not Know
    Osterholm, Michael T.
    Moore, Kristine A.
    Kelley, Nicholas S.
    Brosseau, Lisa M.
    Wong, Gary
    Murphy, Frederick A.
    Peters, Clarence J.
    LeDuc, James W.
    Russell, Phillip K.
    Van Herp, Michel
    Kapetshi, Jimmy
    Muyembe, Jean-Jacques T.
    Ilunga, Benoit Kebela
    Strong, James E.
    Grolla, Allen
    Wolz, Anja
    Kargbo, Brima
    Kargbo, David K.
    Formenty, Pierre
    Sanders, David Avram
    Kobinger, Gary P.
    MBIO, 2015, 6 (02):
  • [7] Pharmacogenetics in older people: what we know and what we need to know
    Seripa, Davide
    Paroni, Giulia
    Urbano, Maria
    Santini, Stefano A.
    D'Onofrio, Grazia
    Pilotto, Alberto
    JOURNAL OF NEPHROLOGY, 2012, 25 : S38 - S47
  • [8] Zika Virus in Semen: What We Know and What We Need to Know
    Gornet, Megan E.
    Bracero, Nabal J.
    Segars, James H.
    SEMINARS IN REPRODUCTIVE MEDICINE, 2016, 34 (05) : 285 - 292
  • [9] Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know
    Jones, Drew R.
    Miller, Grover P.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (07) : 857 - 874
  • [10] What we know and what the future holds
    O'Rahilly, Steve
    JOURNAL OF ENDOCRINOLOGY, 2014, 223 (01) : E1 - E3